- Provisional CDC Guidelines for the Use and Safety Monitoring of . . .
Because bedaquiline has an extremely long terminal half-life (4–5 months), acquired resistance might occur when bedaquiline is the sole effective anti-TB drug in circulation Prescribers should consider discontinuation of bedaquiline 4–5 months before scheduled termination of other drugs in the regimen to reduce or avoid an extended period
- Provisional CDC Guidelines for the Use and Safety Monitoring of . . .
labeling for bedaquiline Bedaquiline should be used with clinical expert consultation as part of combination therapy (minimum four-drug treatment regimen) and administered by direct observation to adults aged ≥18 years with a diagnosis of pulmonary MDR TB (Food and Drug Administration SIRTURO [bedaquiline] tablets label
- Treatment for Drug-Resistant Tuberculosis Disease - CDC
People initiating treatment for MDR or rifampin-resistant TB but ineligible for BPaL (e g , resistance or intolerance to bedaquiline, pretomanid, or linezolid; severe extrapulmonary TB; pregnant; lactating; or aged less than 14 years) can receive an individualized regimen based on the 2019 guidelines Treatment of Drug-Resistant Tuberculosis
- Updates to Provisional Guidance for the Use of Pretomanid as Part of a . . .
Today, CDC released updates to the 2022 "Provisional CDC Guidance for the Use of Pretomanid as part of a Regimen [Bedaquiline, Pretomanid, and Linezolid (BPaL)] to Treat Drug-Resistant Tuberculosis Disease " Updates include: A recommendation for an initial linezolid dose of 600 mg when using the BPaL regimen in the treatment of adults,
- Molecular Detection of Drug Resistance (MDDR) in Mycobacterium . . .
Additionally, for new and repurposed drugs (e g , clofazimine, bedaquiline, and linezolid), we are continuing to learn more about mechanisms of resistance Thus, the interpretation of both DNA sequencing results and results from growth-based methods must be considered in context with specific criteria and test limitations for each individual
- Notes from the Field - Centers for Disease Control and Prevention
acid (PAS), linezolid, clofazimine, and bedaquiline Given the limited treatment options, the patient began a regimen of beda - quiline, clofazimine, linezolid, PAS, and cycloserine In light of the extensively drug-resistant (XDR) disease and potential for limited drug tolerability, inclusion of delamanid, which is not
- Clinical Guidelines | Tuberculosis (TB) | CDC
This page provides a list of selected clinical guidelines related to tuberculosis (TB) topics Guidelines are sorted by topics: testing and diagnosis, treatment, drug resistance, infection control, and specific populations
- Clinical Overview of Drug-Resistant Tuberculosis Disease
Disease rates In 2023, resistance to at least isoniazid at initial diagnosis was reported for 589 (8 5%) cases in the United States, including 100 (1 4%) cases of multidrug-resistant TB disease
|